Musa Yilmaz

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (18)

Hussein A. Abbas

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Anand Ashwin Patel

UNITED STATES

View details

Jayastu Senapati

Assistant professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Alex Bataller Torralba

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Ghayas C. Issa

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Rashmi Kanagal Shamanna

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Fadi Haddad

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Sanam Loghavi

UNITED STATES

View details

Koji Sasaki

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Nitin Jain

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Farhad Ravandi

Professor of Medicine, Chief Section of AML

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Nicholas J. Short

UNITED STATES

View details

PRITHVIRAJ BOSE

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Patrick Reville

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Yesid Alvarado Valero

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Elias J. Jabbour

UNITED STATES

View details

Courtney D. DiNardo

UNITED STATES

View details

Naval G. Daver

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Musa Yilmaz

Research Interests

Explore related searches

Contact this professor

Articles (20)

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis

Cytomolecular Mechanisms of Relapse and Post‐Relapse Outcomes After Frontline FLT3 Inhibitor‐Based Therapy in FLT3‐Mutated AML

Hyper‐CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome‐Negative B‐Cell Acute Lymphoblastic Leukemia

CD123 expression and its correlation with mutation profile in acute myeloid leukaemia

Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome

A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia

Current status and research directions in acute myeloid leukemia

Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease

Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis

The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors

Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia

Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis

Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia

Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes

Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab

Collaborators (18)

Hussein A. Abbas

Anand Ashwin Patel

Jayastu Senapati

Alex Bataller Torralba

Ghayas C. Issa

Rashmi Kanagal Shamanna

Fadi Haddad

Sanam Loghavi

Koji Sasaki

Nitin Jain

Farhad Ravandi

Nicholas J. Short

PRITHVIRAJ BOSE

Patrick Reville

Yesid Alvarado Valero

Elias J. Jabbour

Courtney D. DiNardo

Naval G. Daver

Make your next move.